Cartesian Therapeutics
Open
$8.99
Prev. Close
$8.99
High
$9.04
Low
$8.97
Market Snapshot
$239.91M
-1.6
-10.92
$38.91M
75
Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in mRNA cell therapies for the treatment of autoimmune diseases. The company is headquartered in Frederick, Maryland and currently employs 75 full-time employees. The company went IPO on 2016-06-22. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.
Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in mRNA cell therapies for the treatment of autoimmune diseases. The company is headquartered in Frederick, Maryland and currently employs 75 full-time employees. The company went IPO on 2016-06-22. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.
Recently from Cashu
Cartesian Therapeutics Advances RNA Therapies and Strategic Partnerships for Future Growth
Advancing RNA-Targeted Therapies: Cartesian Therapeutics' Bold Pipeline Development Cartesian Therapeutics is making notable strides in the biotechnology sector, particularly in the area of RNA-target…
Cartesian Therapeutics Advances RNA-Targeted Therapies Amid Revenue Growth and Strategic Innovations
Advancing RNA-Targeted Therapies: Cartesian Therapeutics' Commitment to Innovation Cartesian Therapeutics announces significant advancements in its therapeutic pipeline, particularly concentrating on…
Nipocalimab Shows Promise in Lupus Treatment: A Breakthrough for Cartesian Therapeutics
Nipocalimab’s Promising Efficacy in Lupus Treatment: A Breakthrough in Autoimmune Research Johnson & Johnson (NYSE: JNJ) recently unveils topline results from the Phase 2b JASMINE study, which evaluat…
Cartesian Therapeutics' Descartes-08 Shows Promise in Treating Systemic Lupus Erythematosus
Cartesian Therapeutics Advances Cell Therapy Research for Lupus Management Cartesian Therapeutics, Inc. has announced promising initial findings from its ongoing Phase 2 open-label trial of Descartes-…